Hosted on MSN12mon
Teva’s Ajovy yields positive data in post-hoc migraine analysis
The Phase III trial evaluated the safety and efficacy of monthly and quarterly subcutaneous injections of Ajovy compared to placebo in subjects with chronic migraine or episodic migraine.
pharmaphorum18d
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy
Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed another drug in the class – Teva’s Ajovy – in draft guidance.